BR112018069105A2 - pirimidinas e variantes das mesmas, e usos para tais - Google Patents

pirimidinas e variantes das mesmas, e usos para tais

Info

Publication number
BR112018069105A2
BR112018069105A2 BR112018069105A BR112018069105A BR112018069105A2 BR 112018069105 A2 BR112018069105 A2 BR 112018069105A2 BR 112018069105 A BR112018069105 A BR 112018069105A BR 112018069105 A BR112018069105 A BR 112018069105A BR 112018069105 A2 BR112018069105 A2 BR 112018069105A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
variants
present
potential treatment
provides
Prior art date
Application number
BR112018069105A
Other languages
English (en)
Inventor
P Ford Anthony
R Gever Joel
Ibrahim Prabha
Charles Hawley Ronald
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of BR112018069105A2 publication Critical patent/BR112018069105A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção fornece compostos de pirimidina de fórmula 1 e usos das mesmas, por exemplo, para o tratamento potencial de doenças associadas com receptores purinérgicos p2x. em certos aspectos, a presente invenção fornece antagonistas de p2x3 e/ou p2x2/3 que são úteis, por exemplo, para o tratamento potencial de doenças, condições e transtornos de órgãos viscerais, cardiovasculares e relacionados à dor.
BR112018069105A 2016-03-25 2017-03-20 pirimidinas e variantes das mesmas, e usos para tais BR112018069105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (1)

Publication Number Publication Date
BR112018069105A2 true BR112018069105A2 (pt) 2019-01-29

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069105A BR112018069105A2 (pt) 2016-03-25 2017-03-20 pirimidinas e variantes das mesmas, e usos para tais

Country Status (12)

Country Link
US (2) US10662162B2 (pt)
EP (1) EP3433258B1 (pt)
JP (1) JP6902045B2 (pt)
KR (1) KR102377805B1 (pt)
CN (1) CN108779119B (pt)
AU (1) AU2017237929B2 (pt)
BR (1) BR112018069105A2 (pt)
CA (1) CA3018180C (pt)
MA (1) MA44489A (pt)
MX (1) MX2018011622A (pt)
RU (1) RU2760733C2 (pt)
WO (1) WO2017165255A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430000B1 (en) 2016-03-14 2022-12-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
US10662162B2 (en) 2016-03-25 2020-05-26 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
RU2769693C2 (ru) 2016-12-19 2022-04-05 Новартис Аг Новые производные пиколиновой кислоты и их применение в качестве промежуточных соединений
BR112019012340B1 (pt) * 2016-12-20 2022-01-11 Afferent Pharmaceuticals, Inc. Forma a de citrato cristalino de 5-(2,4-diamino-pirimidin-5-iloxi)-4-isopropil-2-metoxibenzenossulfonamida, bem como sua composição farmacêutica e usos
CN117186068A (zh) 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
SG11202111907UA (en) * 2019-04-30 2021-11-29 Beijing Tide Pharmaceutical Co Ltd Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
US20220211703A1 (en) * 2019-04-30 2022-07-07 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
MX2021013347A (es) * 2019-04-30 2022-01-24 Beijing Tide Pharmaceutical Co Ltd Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.
JP2022535852A (ja) * 2019-06-06 2022-08-10 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
CA2369945A1 (en) * 1999-04-06 2000-10-12 James L. Kelley Neurotrophic thio substituted pyrimidines
MXPA03005610A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
DK1725540T5 (da) * 2004-03-05 2012-10-22 Hoffmann La Roche Diaminopyrimidiner som p2x3- og p2x2/3-antagonister
CA2619919C (en) * 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1924566B1 (en) * 2005-09-01 2016-01-13 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
CN101253159B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
AU2007304280B2 (en) * 2006-10-04 2013-01-31 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
WO2008104472A1 (en) 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
MX2010004705A (es) * 2007-10-31 2010-05-27 Nissan Chemical Ind Ltd Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
MY195728A (en) * 2013-08-23 2023-02-07 Afferent Pharmaceuticals Inc Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough
EP3981406A1 (en) * 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
EP3430000B1 (en) * 2016-03-14 2022-12-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
US10662162B2 (en) 2016-03-25 2020-05-26 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor

Also Published As

Publication number Publication date
JP6902045B2 (ja) 2021-07-14
AU2017237929B2 (en) 2021-04-15
KR102377805B1 (ko) 2022-03-22
CN108779119A (zh) 2018-11-09
WO2017165255A1 (en) 2017-09-28
US11230532B2 (en) 2022-01-25
MX2018011622A (es) 2019-03-28
EP3433258A1 (en) 2019-01-30
US10662162B2 (en) 2020-05-26
EP3433258A4 (en) 2019-10-30
RU2760733C2 (ru) 2021-11-30
MA44489A (fr) 2019-01-30
RU2018137032A3 (pt) 2020-05-22
KR20180128015A (ko) 2018-11-30
CN108779119B (zh) 2022-02-08
CA3018180A1 (en) 2017-09-28
AU2017237929A1 (en) 2018-09-13
RU2018137032A (ru) 2020-04-27
EP3433258B1 (en) 2023-07-19
US20200239421A1 (en) 2020-07-30
CA3018180C (en) 2024-02-20
JP2019510025A (ja) 2019-04-11
US20190055202A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
BR112018068399A2 (pt) pirimidinas e variantes das mesmas e usos para as mesmas
BR112018069105A2 (pt) pirimidinas e variantes das mesmas, e usos para tais
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CO2020001879A2 (es) Compuesto heterocíclico y su uso
BR112018076090A2 (pt) vírus adeno-associados variantes e métodos de utilização
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
CY1124918T1 (el) Ρυθμιστες ccr2
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
FR24C1010I1 (fr) Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux
DK3506909T3 (da) 4'-phosphatanaloger og oligonukleotider omfattende samme
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
CL2018003556A1 (es) Anticuerpos anti-ige.
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
BR112019010342A2 (pt) composições do irna de serpina1 e métodos de uso destas
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
MA46430A (fr) Thérapie combinée d'agonistes de cnp à libération contrôlée
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
CY1123013T1 (el) Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 487/04

Ipc: C07D 487/04 (2006.01), C07D 239/48 (2006.01), C07D

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: AFFERENT PHARMACEUTICALS INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]